QWQihui Wu

Qihui Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qihui Wu has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exome Sequencing of 963 Chinese Families Identifies Novel Epilepsy Candidate Genes

    by Yu Ma, Ke Su, GuangQin Lu, Mingshan Zhou, Xia Guan, Yihan Liu, Jie Wang, Chengjie Li, Yu Liu, Tianqi Wang, et al.

    Background: The genetic architecture of pediatric epilepsy remains incompletely understood, particularly in non-European populations. We aimed to characterize the genetic landscape of pediatric epilepsy in a large Chinese cohort and identify novel candidate genes.Methods: We performed exome sequencing in 963 Chinese pediatric proband–parent trios with diverse epilepsy phenotypes. Variants in established epilepsy-associated genes were systematically assessed, and 582 genetically unsolved trios underwent bioinformatic filtering and prioritization to identify novel candidate genes. Prioritized candidates were subsequently evaluated using zebrafish and cellular models.Findings: Pathogenic or likely pathogenic variants in established epilepsy-associated genes were identified in 39.6% of the cohort, with SCN1A, KCNQ2, and DEPDC5 most frequently affected. Five novel candidate genes—ADCY2, CRTC2, CSMD1, CSMD2, and SGSM2—harbored rare, likely damaging variants in at least two unrelated probands. Functional studies provided experimental support for these candidates, with CRTC2 showing consistent functional effects across zebrafish and cellular models and being associated with a broad phenotypic spectrum.Interpretation: These findings expand the genetic landscape of pediatric epilepsy in a Chinese population and identify five candidate genes supported by convergent genetic and functional evidence. Integrating large-scale genomic analysis with experimental validation provides a framework for epilepsy gene discovery and may facilitate the molecular characterization of genetically unresolved pediatric epilepsy.Funding: National Key Research and Development Program of China, National Natural Science Foundation of China, the 111 Project, and Shanghai Municipal Science and Technology, the Science and Technology Innovation Plan of Shanghai Science and Technology Commission, Shanghai Municipal Science and Technology Major Project, ZJ Lab, Shanghai Center for Brain Science and Brain-Inspired Technology, the Shanghai Fourth People's Hospital affiliated to Tongji University School of Medicine, the Fundamental Research Funds for the Central Universities, the Shanghai Pujiang Program, the Ningxia Hui Autonomous Region Key Research and Development Project, the Science and Technology Commission of Shanghai Municipality (STCSM) grant, and Tongji University Medicine-X Interdisciplinary Research Initiative.

  • Open Access

    Preclinical assessment of intravenous human ficolin-2 administration for Alzheimer's disease

    by Xinwei Huang, Yihan Liu, Qingyuan Miao, Hong Zhang, Xin Tang, Ban Feng, Lushun Zhang, Tingting Dan, Li Tian, Peilin Cong, et al.

  • Open Access

    Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006–2025)

    by Ming Zhang, Wenshuo Yang, Junxin Wang, Biqi Zou, Jialin C. Zheng, Qihui Wu, Ge Gao

    Amyotrophic lateral sclerosis (ALS) remains a major therapeutic challenge, with immune dysregulation increasingly recognized as a critical driver of disease progression. Despite extensive mechanistic research, no immunotherapeutic approach has achieved consistent disease-modifying effects, raising questions about whether this translational gap reflects biological complexity or structural misalignment within the research ecosystem. To characterize the intellectual evolution of ALS immunotherapeutics research, identify immune targets with translational potential, and evaluate collaboration patterns that may influence translational efficiency, we performed a bibliometric analysis of 2,256 publications indexed in Web of Science and Scopus using network-based approaches including co-citation clustering, keyword co-occurrence, and citation burst detection implemented in CiteSpace, VOSviewer, and R-Bibliometrix. Publication output increased 8.4-fold over the study period, delineating three developmental phases. Thematic analyses revealed a shift from early emphasis on microglial biology and SOD1-based models toward recent focus areas including the gut-brain axis, C9orf72-associated immune dysregulation, and advanced immunomodulatory strategies. Collaboration networks remain predominantly regional despite strong contributions from the United States, Europe, and Asia, with limited integration between mechanistic research groups and clinical trial consortia. Among immune-directed therapeutic strategies, regulatory T cell modulation and microglial-targeted approaches exhibit the highest translational readiness. These findings suggest that the lack of effective ALS immunotherapeutics reflects not only biological complexity but also structural and strategic misalignment within the research ecosystem. This bibliometric analysis provides a systems-level framework to guide more integrated translational strategies in ALS immunotherapeutics development.

  • Top Cited Papers
    Open Access

    Maternal obesity induces macrophage to myofibroblast transition in kidneys of male offspring through a pathway driven by 20-hydroxyeicosatetraenoic acid

    by Fengbo Zhong, Xingyu Huang, Huiru Sun, Mengxuan Wang, Qi Qi, Xinlin Song, Kai Lin, Zhuozhuo Li, Jiayun Shen, Qiuyu Lu, et al.

    Over 800 million people globally suffer from chronic kidney disease (CKD). Maternal obesity has emerged as a risk factor for CKD in offspring, but the mechanisms remain unclear. In this study, we use mouse models of maternal obesity to investigate macrophage involvement in offspring kidneys. Multi-omics analyses revealed that maternal obesity accelerates kidney disease in male offspring through dysregulated crosstalk between proximal tubules (PT) and macrophages. PT-derived 20-hydroxyeicosatetraenoic acid (20-HETE) promotes mitochondrial hyperactivity and macrophage to myofibroblast transition (MMT) via Ffar1 in macrophages. Targeting 20-HETE or depleting Ffar1 in offspring of obese mothers markedly reduces kidney pathology. Hormone screening identified 3,3,5-Triiodo-L-thyronine (T3) as a factor that enhances Ffar1 expression in macrophages. Mechanistically, the T3 receptor (TRβ) binds to an enhancer we identify upstream of the gene, promoting Ffar1 transcription via the TRβ-P300-BRD4 regulatory axis. These findings highlight T3 and 20-HETE co-activated MMT as a central mechanism to kidney disease in offspring of obese mothers, offering potential therapeutic targets.


  • Open Access

    Serine endopeptidase tripeptidyl peptidase II maintains lysosomal homeostasis to alleviate Parkinson’s disease pathogenesis

    by Chengjie Li, Weixian Kong, Yali Li, Junxin Wang, Yunjie Zou, Yu Liu, Yihan Liu, Linlin Zhou, Long Guo, Dafei Xu, et al.

    Parkinson's disease is neuropathologically characterized by the progressive loss of dopaminergic neurons and the pathological accumulation of α-synuclein. While these hallmarks are well established, the molecular drivers of this irreversible neurodegenerative process are not fully understood. Through an integrated multi-omics approach combining nascent protein mass spectrometry and bulk RNA sequencing of cellular and transgenic Parkinson's disease mouse models, we revealed suppressed serine endopeptidase activity during the early pathogenic stages of the disease. Subsequent functional analyses identified tripeptidyl peptidase II as the principal enzyme mediating serine endopeptidase activity, as demonstrated through a series of biochemical assays. Mechanistic investigations showed that tripeptidyl peptidase II deficiency impairs lysosomal function, prolongs the clearance of α-synuclein fibrillar seeds, and disrupts synaptic homeostasis in hippocampal neurons. Importantly, overexpression of tripeptidyl peptidase II effectively attenuated pathological α-synuclein aggregation and prevented the cell-to-cell propagation of α-synuclein pathology in wild-type mice injected with α-synuclein preformed fibrils. Our findings establish tripeptidyl peptidase II as a critical regulator of lysosome-mediated amyloidogenic seed degradation and reveal its neuroprotective role against α-synuclein-associated synucleinopathies.

  • Open Access

    Translational progress and bottlenecks in neurotransmitter-cancer research [2000–2025]: an integrated bibliometric and interventional trial analysis

    by Ming Zhang, Weihao Sun, Yizhao Ma, Jialin C. Zheng, Qihui Wu, Ge Gao

    Background: Neurotransmitter signaling influences cancer initiation, progression, and therapy response. We systematically characterized the field’s intellectual structure, thematic evolution, and translational trajectory. Methods: We analyzed 2,823 Web of Science articles [2000–2025] with CiteSpace and Bibliometrix, and reviewed 76 interventional trials from ClinicalTrials.gov to assess translational activity, drug-class distribution, and trial design trends. Results: Annual output nearly tripled, with >50% of papers published after 2020. The US led productivity (26.2%) and impact; China showed rapid output growth (18.1%). Oncology trials with tumor efficacy endpoints were dominated by β-adrenergic antagonists (33%), histone deacetylase (HDAC) inhibitors (16%), selective serotonin reuptake inhibitors (SSRIs) (22%), and dopamine modulators (13%). Since 2018, immunotherapy combinations increased (8 trials). Trials were skewed toward early-phase, and trial design heterogeneity and limited biomarker integration were common. Translational linkage was limited: only 4.5% of publications connected to identifiable trials. The neurotransmitter-immune axis emerged as a central translational theme. Conclusions: Neurotransmitter-cancer research has expanded rapidly but shows substantial translational attrition. Findings support continued evaluation of β-blockers in late-phase trials, prioritized testing of SSRI-immunotherapy combinations, and exploration of underrepresented GABAergic and cholinergic pathways. We recommend harmonized preclinical-to-clinical pipelines and accelerated biomarker development to improve translation. This evidence-based map can guide targeted translational strategies in neurotransmitter-directed oncology and precision oncology.

  • Open Access

    Chromogranin A promotes the pathological conversion of α-synuclein at the synapse in Parkinson’s disease

    by Yu Liu, Weixian Kong, Feipeng Zhu, Jinwen Jiang, Cui Li, Jiale Han, Pu Ai, Chengjie Li, Yuwei Wang, Yihan Liu, et al.


  • Open Access

    Aggregation and Propagation of α‐Synuclein in Parkinson's Disease: A Bibliometric Perspective

    by Xinyue Zhang, Yizhao Ma, Ge Gao, Qihui Wu

    Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the aggregation and propagation of alpha‐synuclein (α‐syn), processes that contribute to neuronal dysfunction and cell death. Although substantial progress has been made in understanding α‐syn pathology, a comprehensive bibliometric evaluation of global trends in this field remains lacking. This study aims to systematically map the research landscape surrounding α‐syn aggregation and propagation in PD, offering insights into its molecular mechanisms and clinical relevance. Methods: A bibliometric analysis was conducted using data retrieved from the Web of Science Core Collection (WoSCC) spanning 2005 to 2024. The data were processed and analyzed with R‐Bibliometrix, VOSviewer, and CiteSpace to quantify publication trends, international collaborations, influential authors and institutions, journal impact, and keyword co‐occurrence networks. Results: A total of 3220 relevant articles were identified. The number of annual publications steadily increased, reflecting growing scholarly interest. The United States, China, and the United Kingdom emerged as leading contributors. Robust international collaborations were observed, especially among Western countries, with the University of California System identified as the most prolific institution. Two primary thematic clusters were revealed: (1) “aggregation,” focusing on the roles of “mitochondria” and “lysosomes,” and (2) “propagation,” highlighting the involvement of “exosomes” and “microglia.” Emerging research frontiers included “biomarkers” and “neuroinflammation,” with a recent trend shifting toward studies on the propagation of α‐syn. Conclusion: This study underscores a paradigm shift in PD research from α‐syn aggregation to propagation, emphasizing the significance of exosomes, microglia, and systemic inflammation in disease pathogenesis. These findings provide a comprehensive roadmap for future research, highlighting the need for interdisciplinary collaboration and the development of targeted therapeutic strategies.


  • Open Access

    Dynein‐Dependent Endo‐Lysosomal Degradation Drives Lewy Body Disorders Accompanied by Aβ Pathology

    by Linlin Zhou, Yuwei Wang, Yu Liu, Feipeng Zhu, Ge Gao, Chengjie Li, Pu Ai, Jingying Xu, Junxin Wang, Long Guo, et al.

    Dementia with Lewy bodies (DLB) is a significant cause of dementia. However, the limited availability of animal and cellular models that accurately replicate early DLB pathogenesis hampers the understanding of how Aβ plaques influence α‐synuclein (αSyn) pathologies. This study addresses this gap by co‐culturing primary neurons with adult hippocampal brain slices from either wild‐type or Alzheimer's disease (AD) mice containing abundant Aβ plaques and cytokines. Neurons exposed to AD slices showed impaired dynein‐dependent organelle trafficking, reducing endosome–lysosome fusion and causing defective degradation of amyloidogenic αSyn fibrils, thus increasing αSyn inclusions. Notably, an abnormal pre‐accumulation of dynein in AD mice suggests that dysfunctional dynein may serve as a nucleation site for αSyn aggregation upon exposure to pathogenic fibrils. Furthermore, Rab7 activation successfully restored endo‐lysosomal degradation of αSyn fibrils and reduced inclusion formation in mouse models presenting with both Lewy body and Aβ pathologies. These results highlight the dynein‐dependent endo‐lysosomal pathway as a promising therapeutic target for mitigating αSyn‐related pathologies in co‐existing Aβ burden, characteristic of many DLB cases.